Good point. Doctors either know it's working or not. Given recent volume and increasing institutional ownership I think we have out answer. Thanks.
Recall the $1.9 Million Dollar Fast Track Grand from NIH. Data coming in a few weeks, and given the recent volume plus institutional ownership... Baker Bros, FMR, Broadfin, Millennium, the data is likely positive. Uptrend into data has started. Positive data brings us to $8.
"This study is as an escalating dose study evaluating three dose levels of aerosolized KL4 surfactant and is expected to be completed in the third quarter of 2014."
CUR = CURE. That's what they are shooting for. No other company is even close. If you disagree show me another company this far along towards beating ALS.
Seriously, it's one thing to give an experimental drug to someone. It doesn't take much for a nurse to hook them up to an IV and see what happens, it's another whole ballgame to book an OR, all the associated support staff, and perform a massively invasive procedure on someone's C-Spine. You only do that, if the return exceeds the risk. Given these procedures are continuing to happen at the aforementioned hospitals tells me the researchers and surgeons must believe they are helping patients. To me that suggests NSI-566 is the only possible cure for ALS in the works. Investors just haven't figured that out yet. I'd like to know if any other Biotechs are this far along?
Thanks I just looked at BCLI, they don't seem on par with Neuralstem. For me, what's most interesting about Neuralstem's trials in ALS is that they are being conducted at Emory, UMichigan, and Mass General. For those research hospitals to commit resources and training to operative ALS procedures suggests to me that CUR is in a class all its own. Those are big names putting their reputation behind NSI-566. Not to mention the Neurosurgeons performing these procedures. Agree?
Can anyone point me at other companies that are in any serious active trials for ALS? It would seem to me that Neuralstem will likely end up with the first approved ALS treatment making this stock a tremendous value at todays price. I'm curious if other agree/disagree. Thanks.
No other choice.
I bet the majority of people on this board don't even realize this. I verified it two weeks ago and bought shares then knowing this was easy $$$. Tekmira is the only company with an ongoing FDA trial. I challenge anyone to prove otherwise.
The less Tekmira says the more you know there is material non public discussions happening with the FDA. This stock easily will see $75-$100 a share this week.
Go the the FDA clinical trial website and punch in Ebola. Tekmira is the only company listed with an Ebola drug trial. No other pharmaceutical company is listed - none! Not Glaxo or Mapp. This is the real deal. Go verify it yourself.
That's what you must ask yourself. I say at least $50 Billion. TKMR is headed well over $200 a share.
The CDC already has a potential cure in hand. Why do you think Termkira-Ebola is on clinical hold? This vaccine is years away from approval. Even Sarpeta.'s vaccine candidate was cancelled. Once this becomes clear to everyone TKMR will trade down into the 6's.
It's irrelevant. The CDC already has a treatment, they don't need Tekmira. Tekmira has confirmed that Dr. Brantley was NOT given their vaccine: "Our investigational therapy TKM-Ebola has not been given to either of the Samaritan Purse workers or anyone else infected in the current outbreak, and has not been given to anyone outside of our Phase I trials," it said in an email. I'm sure a lot of people buying this stock don't even know this, they are just falling into the hype, and will lose money.